The proton-pump inhibitor lansoprazole enhances amyloid beta production.
A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Based on a systems biology study to repurpose drugs for AD, we explore the...
Guardado en:
Autores principales: | Nahuai Badiola, Victor Alcalde, Albert Pujol, Lisa-Marie Münter, Gerd Multhaup, Alberto Lleó, Mireia Coma, Montserrat Soler-López, Patrick Aloy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aaaf0f44a49646f28a9a25d4605314d4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The effectiveness and cost of lansoprazole and pantoprazole for stress ulcer prophylaxis in intensive care unit
por: Mega Octavia, et al.
Publicado: (2021) -
Proton pumping accompanies calcification in foraminifera
por: Takashi Toyofuku, et al.
Publicado: (2017) -
Gastric proton pump with two occluded K+ engineered with sodium pump-mimetic mutations
por: Kazuhiro Abe, et al.
Publicado: (2021) -
A natural light-driven inward proton pump
por: Keiichi Inoue, et al.
Publicado: (2016) -
Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations
por: Alai M, et al.
Publicado: (2015)